November 25, 2014: The U.S. Department of Health & Human Services’ Office of Research Integrity announced yesterday its final action on the case of Igor Dzhura, finding that the scientist had “engaged in research misconduct in research supported by U.S. Public Health Services funds.”
November 25, 2014: Genric drugmaker Actavis is aiming to cut its staff and make further moves in China. Chief Executive Officer Brett Saunders told Bloomberg News on Monday. Saunders did not elaborate on how many positions would be eliminated.
November 25, 2014: Genentech, the biotechnology unit of Roche, has decided to only allow a handful of distributors to supply three of the world’s most used cancer drugs. Now, the company is facing scrutiny as the healthcare industry cites delays and cost increases, according to Reuters.
November 25, 2014: U.S. District Judge William Young denied a bid by AstraZeneca and Ranbaxy to bring an early end to a collusion lawsuit that had charged AstraZeneca with signing anticompetitive deals to protect its heartburn medication, Nexium, from competition from generic versions.